In the context of cancer, SETDB2 is often implicated to be involved in tumorigenesis; its overexpression can lead to abnormal H3K9 trimethylation, which results in the silencing of tumor suppressor genes and the promotion of cancer cell proliferation and survival. Here, SETDB2 is linked to cancer.